---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-007060"
form_type: "8-K"
ticker: "PLX"
cik: "0001006281"
company_name: "Protalix BioTherapeutics, Inc."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:08:58.336485+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Protalix BioTherapeutics Q1 revenue up 170% to $10.0M, net loss narrows to $3.6M

## Summary
- Revenues from selling goods $10.0M, up 170% YoY, driven by $5.9M increase in sales to Pfizer.
- Net loss $3.6M ($0.05/sh) vs $4.6M ($0.06/sh) in Q1 2024; cash $34.7M.
- Phase II trial of gout candidate PRX-115 expected to start H2 2025 after positive FIH results.
- R&D expenses $3.5M (+21% YoY) due to clinical pipeline advancement; SG&A down 16% to $2.6M.

## SEC filing metadata
- accession: 0001558370-25-007060
- form_type: 8-K
- ticker: PLX
- cik: 0001006281
- company_name: Protalix BioTherapeutics, Inc.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006281/000155837025007060/0001558370-25-007060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006281/000155837025007060/plx-20250509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-007060
- JSON: https://secwatch.observer/filing/0001558370-25-007060.json
- Plain text: https://secwatch.observer/filing/0001558370-25-007060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.